Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Antibiotics, steroids benefit COPD patients regardless of severity

Pearl Toh
23 Apr 2020

Both antibiotics and systemic corticosteroids reduce treatment failure rates in patients with chronic obstructive pulmonary disease (COPD), regardless of severity of exacerbations, according to a systematic review and meta-analysis of randomized trials.

“Whether all patients, especially those with mild exacerbations treated as outpatients, benefit from treatment with antibiotics and systemic corticosteroids is uncertain,” said the researchers. “Our review lends further support to the practice of treating even mild exacerbations with antibiotics and corticosteroids.”

A total of 68 randomized controlled trials involving adults with mild to severe COPD exacerbations who were treated in out- or inpatient settings (excluding intensive care unit) were included in the analysis. [Ann Intern Med 2020;172:413-422]  

Compared with patients in the control group (placebo or usual care without antibiotics/systemic steroids), those who were treated with antibiotics for 3–14 days were twice as likely to have resolution of exacerbation (odds ratio [OR], 2.03, 95 percent confidence interval [CI], 1.47–2.80) and half as likely to experience treatment failure (OR, 0.54, 95 percent CI, 0.34–0.86). The findings were independent of severity of exacerbations and considered to be of moderate strength of evidence.

Systemic corticosteroids, given for 9–56 days, were also associated with less treatment failure regardless of severity of exacerbations (OR, 0.01, 95 percent CI, 0.00–0.13), although the strength of evidence for this was low.

“Systemic corticosteroids were also associated with reduced dyspnoea… at the end of the intervention at 7 to 9 days in outpatients with mild and inpatients with moderate to severe exacerbation,”  the researchers noted.

Nonetheless, total adverse events (AEs) and endocrine-related AEs were more frequent in the systemic corticosteroid group vs the control group.  

On the other hand, other pharmacological interventions showed either limited or inconclusive evidence of efficacy for the outcomes measured, or at best, improvements only in lung function. These agents tested included short-acting bronchodilators, aminophyllines, magnesium sulfate, inhaled corticosteroids, and anti-inflammatory agents.

“We found insufficient or no evidence supporting the use of pharmacologic treatments other than antibiotics and systemic corticosteroids,” the researchers concluded.

“Our review found a lack of good-quality, reliable evidence to answer many of the important clinical questions surrounding treatment of patients with exacerbation of COPD,” they added. “There was also insufficient or no evidence informing the optimal choice of antibiotic or corticosteroid treatment regimens (agent type, dosage, application route, or duration of treatment).”

In particular, trials on systemic corticosteroids should evaluate the effects of treatment stratified by baseline eosinophil count in order to assess if the benefits of such treatment are limited only to certain patient subgroup with high eosinophil counts, the researchers pointed out.

“Future studies should focus on high-quality study design and patient-centered outcomes particularly clinical resolution of exacerbation and risk for repeated exacerbation, rather than lung function measurements,” they suggested.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.